欧洲语音/语音生物标记市场按平台类型、适应症、应用类型、最终用户和国家分類的分析与预测（2025 年至 2035 年）

欧洲语音/言语生物标记市场预计将从 2024 年的 3.352 亿美元增长到 2035 年的 16.997 亿美元，在 2025-2035 年预测期内的复合年增长率为 16.0%。

欧洲正在开发和使用声音或语音生物标记来识别、追踪和预测健康问题。这些生物标记是基于人类声音的特征。作为数位生物标记的子集，它们使用可量化的声音特征，例如音高、音调、频率、振幅、语速和颤抖。这些特征代表生理和病理状况，从而实现非侵入性诊断和持续的健康监测。

软体平台、硬体辅助诊断工具和整合远距远端保健解决方案用于分析语音数据以进行早期疾病检测，特别是神经、精神、呼吸、心血管和认知疾病，都是欧洲语音生物标记市场的一部分，不仅应用于临床环境，还应用于健康、职业健康、认知表现和防御。

欧洲市场的成长受到人工智慧的进步、远距医疗基础设施的扩大以及与传统诊断方法相比对具有成本效益、可扩展和快速筛检工具的需求的推动。

市场介绍

欧洲语音/语音生物标记市场是数位健康生态系统中的新兴市场，该生态系统利用人类声音特征作为可量化的生物指标来识别、追踪和预测疾病。这些生物标记会侦测音高、音调、频率、振幅、语速和颤抖等声音特征，这些特征可能预示着潜在的生理或病理状况。语音生物标记能够实现非侵入式即时监测，被定位为远端病患管理、早期疾病检测和个人化医疗的突破性工具。

在欧洲，市场涵盖软体平台、人工智慧主导的诊断解决方案和硬体辅助工具，在临床和居家照护环境中的应用日益广泛。语音分析可以提供持续、经济实惠且患者友好的监测选项，随着人们对神经系统疾病、心理健康问题和慢性疾病的了解不断增加，语音分析也越来越受到关注。此外，机器学习 (ML) 与人工智慧 (AI) 的整合可以提高预测准确性，并实现在不同人群中的可扩展部署。

研究机构、技术开发商、数位健康新兴企业和医疗保健提供者是支持语音诊断快速发展的关键参与者。欧洲法规结构正在不断发展，以促进这些数位生物标记物的使用，同时维护资料隐私并符合医疗设备标准。随着市场的发展，欧洲预计将成为语音生物标记物创新的中心，重点关注个人化医疗和有效的医疗保健服务。

市场区隔

细分一：依平台类型

• 云端基础
• 基于网路

细分2：依适应症类型

• 神经系统疾病
• 精神疾病
• 呼吸系统疾病
• 心血管疾病
• 其他的

细分 3：按应用程式类型

• 诊断
• 监控
• 临床研究
• 其他的

细分 4：按最终用户

• 医院
• CRO
• 研究所

细分5：按地区

• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的

欧洲语音/言语生物标记市场趋势、驱动因素与挑战

市场趋势

• 人工智慧和机器学习的融合度不断提高，用于基于语音的情绪、压力和疾病检测。
• 数位生物标记在临床试验和药物开发的应用越来越多，特别是针对神经和精神疾病。
• 远端医疗和远端监控平台的扩展以及即时语音分析的采用增加。
• 一家健康科技公司和一家製药公司合作开发语音诊断工具。
• 利用语音生物标记进行早期疾病预测和病人参与行动医疗应用程式的兴起。

关键市场驱动因素

• 神经退化性疾病（如帕金森氏症、忧郁症、阿兹海默症）的盛行率不断上升。
• 欧洲数位健康创新的监管灵活性（欧盟 MDR 与基于人工智慧的医疗工具的一致性）。
• 穿戴式装置和智慧型手机的使用日益增多，将增强语音资料收集的途径。
• 对个人化医疗和非侵入性、持续监测解决方案的需求不断增长。
• 增加临床生物标记研究的研发投入和政府资助。

市场挑战

• 缺乏针对语音生物标记的准确性和可重复性的标准化检验框架。
• 医疗系统和消费者应用程式之间的资料隐私和互通性问题。
• 欧洲各国针对数位和语音诊断的报销模式不透明。
• 人工智慧模型开发和临床试验的资本成本高昂，且缺乏熟练的专家。
• 监管复杂性延迟了基于人工智慧和语音诊断解决方案的核准。

产品/创新策略：本报告深入探讨了语音/语音生物标记的最新技术进步，使公司能够推动创新并开发出满足市场需求的尖端产品。

成长/行销策略：透过提供全面的市场分析和识别关键的成长机会，公司能够获得制定有针对性的行销策略和有效扩大其市场占有率的知识。

竞争策略：该报告包括全面的竞争格局分析，以了解语音/声音生物标记市场中竞争对手的优势和劣势，并制定有效的策略以在市场上获得竞争优势。

监管与合规策略：提供有关声音/声音生物标誌物的法律规范、核准和行业指南的最新信息，使公司能够保持合规并加速新声音/声音生物标誌物的市场进入。

投资和业务扩大策略：透过分析市场趋势、资金筹措模式和合作机会，我们帮助公司做出明智的投资决策并确定业务成长的潜在併购机会。

主要市场参与企业和竞争对手的摘要

公司简介是根据从主要专家收集的意见以及对公司覆盖范围、产品系列和市场渗透率的分析而选择的。

市场上一些值得注意的参与者包括：

• auddering GmbH
• EVOCAL Health GmbH
• VoiceMed Italia Srl
• Zana Technologies GmbH

目录

执行摘要

第 1 章欧洲语音生物标记市场：产业展望

• 产业展望
  • 市场概况与生态系统
  • 竞争力评估
  • 机会评估
  • 资金筹措分析
• 市场动态
  • 趋势、驱动因素、挑战和机会：评估当前和未来的影响
• 趋势
  • 将AI/ML整合到语音生物标记技术中
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场挑战

第二章 区域

• 欧洲
  • 区域概况
  • 市场成长动力
  • 成长抑制因素
  • 市场规模及预测
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他的

第三章：竞争格局与公司概况

• 公司简介
  • audEERING GmbH
  • EVOCAL Health GmbH
  • VoiceMed Italia srl
  • Zana Technologies GmbH

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Europe Voice/Vocal Biomarker Market

The Europe voice/vocal biomarker market is projected to reach $1,699.7 million by 2035 from $335.2 million in 2024, growing at a CAGR of 16.0% during the forecast period 2025-2035. Vocal or voice biomarkers are developed and used in Europe to identify, track, and forecast health issues. These biomarkers are based on the features of human voices. They use quantifiable voice characteristics, such as pitch, tone, frequency, amplitude, speech rate, and tremor, as a subset of digital biomarkers. These characteristics represent physiological and pathological states and allow for non-invasive diagnoses and ongoing health monitoring.

Software platforms, hardware-assisted diagnostic tools, and telehealth-integrated solutions that analyze voice data for early disease detection-particularly in neurological, mental health, respiratory, cardiovascular, and cognitive disorders-are all part of the European voice biomarker market. Beyond clinical use, applications extend to wellness, occupational health, cognitive performance, and defense sectors.

Market growth in Europe is propelled by advances in AI, expanding remote healthcare infrastructure, and the demand for cost-effective, scalable, and rapid screening tools compared to conventional diagnostic methods.

Market Introduction

An emerging market within the larger digital health ecosystem is the European voice and vocal biomarker market, which uses the features of human voices as quantifiable biological indicators to identify, track, and forecast medical disorders. These biomarkers examine vocal characteristics that may indicate underlying physiological or pathological conditions, including pitch, tone, frequency, amplitude, speech pace, and tremor. Voice biomarkers are positioned as a game-changing tool for remote patient management, early illness identification, and personalized healthcare by facilitating non-invasive, real-time monitoring.

In Europe, the market spans software platforms, AI-driven diagnostic solutions, and hardware-assisted tools, with increasing adoption across clinical and home-care settings. Voice analysis can offer continuous, affordable, and patient-friendly monitoring options, which is generating interest as knowledge of neurological problems, mental health issues, and chronic diseases grows. Additionally, integrating machine learning (ML) and artificial intelligence (AI) improves prediction accuracy and permits scalable deployment across a range of demographics.

Research institutes, technology developers, digital health startups, and healthcare providers are important players who support the quick development of speech-based diagnostics. While maintaining data privacy and adherence to medical device standards, European regulatory frameworks are changing to facilitate the use of these digital biomarkers. Europe is anticipated to develop as a center for voice biomarker innovation as the market evolves, with a focus on individualized medication and effective healthcare delivery.

Market Segmentation:

Segmentation 1: By Platform Type

• Cloud-based
• Web-based

Segmentation 2: By Indication Type

• Neurological Disorder
• Mental Health Disorder
• Respiratory Diseases
• Cardiovascular Disease
• Others

Segmentation 3: By Application Type

• Diagnostics
• Monitoring
• Clinical Research
• Others

Segmentation 4: By End User

• Hospitals
• CROs
• Research Institutions

Segmentation 5: By Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Voice/Vocal Biomarker Market Trends, Drivers & Challenges

Market Trends

• Increasing integration of AI and machine learning for voice-based emotion, stress, and disease detection.
• Growing adoption of digital biomarkers in clinical trials and drug development, especially for neurological and psychiatric disorders.
• Expansion of telehealth and remote monitoring platforms, driving real-time voice analytics adoption.
• Partnerships between health-tech firms and pharmaceutical companies to develop voice-enabled diagnostic tools.
• Rise of mobile health apps leveraging vocal biomarkers for early disease prediction and patient engagement.

Key Market Drivers

• Rising prevalence of neurodegenerative and mental health disorders (e.g., Parkinson's, depression, Alzheimer's).
• Regulatory flexibility toward digital health innovations in Europe (EU MDR alignment with AI-based medical tools).
• Increasing use of wearable devices and smartphones enhancing access to voice-data collection.
• Growth in personalized medicine and demand for non-invasive, continuous monitoring solutions.
• Increasing R&D investments and government funding for clinical biomarker research.

Market Challenges

• Lack of standardized validation frameworks for voice biomarker accuracy and reproducibility.
• Data privacy and interoperability issues between medical systems and consumer applications.
• Uncertain reimbursement models for digital and voice-based diagnostics across European nations.
• High capital costs and shortage of skilled professionals for AI model development and clinical testing.
• Regulatory complexity delaying approval of AI-based and vocal-diagnostic solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in voice/vocal biomarker, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in Voice/Vocal Biomarker and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to Voice/Vocal Biomarker, ensuring organizations stay compliant and accelerate market entry for new voice/vocal biomarker

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in the market are:

• auddering GmbH
• EVOCAL Health GmbH
• VoiceMed Italia Srl
• Zana Technologies GmbH

Table of Contents

Executive Summary

Scope and Definition

1 Europe Voice/Vocal Biomarker Market: Industry Outlook

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
    • 1.1.1.1 Future Direction and Emerging Technology
  • 1.1.2 Competitive Assessment
    • 1.1.2.1 Go-to-Market Strategy
    • 1.1.2.2 Competitive Landscape
      • 1.1.2.2.1 Business Strategies
  • 1.1.3 Opportunity Assessment
    • 1.1.3.1 Strategic Opportunities of Stakeholders in Voice/Vocal Biomarker Market
    • 1.1.3.2 Market Opportunity and Demand Analysis
  • 1.1.4 Funding Analysis
• 1.2 Market Dynamics
  • 1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
• 1.3 Trends
  • 1.3.1 Integration of AI/ML into Vocal Biomarker Technologies
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rising Application of Vocal Biomarkers as Novel Diagnostic and Monitoring Aid
    • 1.3.2.2 Increasing Demand for Remote and Non-Invasive Health Monitoring
    • 1.3.2.3 Adoption of Vocal Biomarkers in Health and Wellness Apps
  • 1.3.3 Market Restraints
    • 1.3.3.1 Regulatory Challenges and Unclear Guidelines
      • 1.3.3.1.1 Regulatory Approval for AI/ML-based Vocal Biomarker Applications
      • 1.3.3.1.2 Need for Clinical Validation
    • 1.3.3.2 Integration of Vocal Biomarker Technologies in Healthcare Systems and Associated Complexities
      • 1.3.3.2.1 Integration with EHR
      • 1.3.3.2.2 Integration with Telehealth Platforms
      • 1.3.3.2.3 Integration with Wearables and Smart Devices
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Early Disease Detection and Prevention using Vocal Biomarkers
    • 1.3.4.2 Increasing Number of Clinical Trials and Research on Vocal Biomarker
  • 1.3.5 Market Challenges
    • 1.3.5.1 Technology Limitations and Accuracy Issues
    • 1.3.5.2 Lack of Standardized Regulations on Vocal Biomarker

2 Region

• 2.1 Europe
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Market Sizing and Forecast
    • 2.1.4.1 Europe Voice/Vocal Biomarkers Market, by Platform Type
    • 2.1.4.2 Europe Voice/Vocal Biomarkers Market, by Application
    • 2.1.4.3 Europe Voice/Vocal Biomarkers Market, by Indication
    • 2.1.4.4 Europe Voice/Vocal Biomarkers Market, by End User
    • 2.1.4.5 Europe Voice/Vocal Biomarkers Market, by Country
  • 2.1.5 U.K.
    • 2.1.5.1 Country Overview
      • 2.1.5.1.1 Market Sizing and Forecast
  • 2.1.6 Germany
    • 2.1.6.1 Country Overview
      • 2.1.6.1.1 Market Sizing and Forecast
  • 2.1.7 France
    • 2.1.7.1 Country Overview
      • 2.1.7.1.1 Market Sizing and Forecast
  • 2.1.8 Italy
    • 2.1.8.1 Country Overview
      • 2.1.8.1.1 Market Sizing and Forecast
  • 2.1.9 Spain
    • 2.1.9.1 Country Overview
      • 2.1.9.1.1 Market Sizing and Forecast
  • 2.1.10 Rest-of-the- Europe
    • 2.1.10.1 Country Overview
      • 2.1.10.1.1 Market Sizing and Forecast

3 Competitive Landscape and Company Profiles

• 3.1 Company Profiles
  • 3.1.1 audEERING GmbH
    • 3.1.1.1 Overview
  • 3.1.2 EVOCAL Health GmbH
    • 3.1.2.1 Overview
  • 3.1.3 VoiceMed Italia srl
    • 3.1.3.1 Overview
  • 3.1.4 Zana Technologies GmbH
    • 3.1.4.1 Overview

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Voice/Vocal Biomarker Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Europe Voice/Vocal Biomarker Market, 2024-2035
• Figure 3: Europe Voice/Vocal Biomarker Market Snapshot
• Figure 4: Voice/Vocal Biomarker Market, $Million, 2024 and 2035
• Figure 5: Europe Voice/Vocal Biomarker Market (by Platform Type), $Million, 2024, 2028, and 2035
• Figure 6: Europe Voice/Vocal Biomarker Market (by Application Type), $Million, 2024, 2028, and 2035
• Figure 7: Europe Voice/Vocal Biomarker Market (by Indication Type), $Million, 2024, 2028, and 2035
• Figure 8: Europe Voice/Vocal Biomarker Market (by End User), $Million, 2024, 2028, and 2035
• Figure 9: Europe Voice/Vocal Biomarker Market Segmentation
• Figure 10: Go-to-Market Strategy of Major Players
• Figure 11: Go-to-Market Strategy of Major Players
• Figure 12: Go-to-Market Strategy of Major Players
• Figure 13: Companies Offering AI-based Vocal Biomarkers for Early Disease Detection
• Figure 14: Europe Voice/Vocal Biomarkers Market, $Million, 2024-2035
• Figure 15: U.K. Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 16: Germany Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 17: France Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 18: Italy Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 19: Spain Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 20: Rest-of-the Europe Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 21: Inclusion and Exclusion Criteria for Europe Voice/Vocal Biomarker Market
• Figure 22: Data Triangulation
• Figure 23: Top-Down and Bottom-Up Approach
• Figure 24: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Recent Funding in Europe Voice/Vocal Biomarker Market
• Table 3: Use of AI/ML Technology by Companies
• Table 4: Key Market Players and their Major Contributions
• Table 5: Few Clinical Trials Related to Voice Biomarker
• Table 6: Voice/Vocal Biomarkers Market (by Region), $Million, 2024-2035
• Table 7: Europe Voice/Vocal Biomarkers Market (by Platform Type), $Million, 2024-2035
• Table 8: Europe Voice/Vocal Biomarkers Market (by Application), $Million, 2024-2035
• Table 9: Europe Voice/Vocal Biomarkers Market (by Indication), $Million, 2024-2035
• Table 10: Europe Voice/Vocal Biomarkers Market (by End User), $Million, 2024-2035
• Table 11: Europe Voice/Vocal Biomarkers Market (by Country), $Million, 2024-2035